Opendata, web and dolomites

EJP RD SIGNED

European Joint Programme on Rare Diseases

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 EJP RD project word cloud

Explore the words cloud of the EJP RD project. It provides you a very rough idea of what is the project "EJP RD" about.

actions    improvement    ecosystem    suffering    efficacy    pillars    p1    scientific    benefit    recommendation    2009    prime    unnecessary    centers    capacity    appears    networks    accelerated    building    area    central    world    settings    materials    joint    demonstration    efficacious    tests    circle    data    fundamental    patients    overcome    coupled    scaling    clinical    faster    decrease    social    hardship    tools    service    epidemiological    international    competitiveness    omics    sustainable    innovation    outcomes    profit    integration    care    assisted    financial    fragmentation    sharing    maximize    reuse    concerted    diseases    translation    generation    medical    promotion    economic    virtuous    progress    health    rare    p4    coordinated    prolonged    council    151    context    rd    p2    supporting    p3    reference    effort    introduction    linking    structuration    efficient    services    model    02    as    ejp    interpretation    adapting    types    massive   

Project "EJP RD" data sheet

The following table provides information about the project.

Coordinator
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE 

Organization address
address: RUE DE TOLBIAC 101
city: PARIS
postcode: 75654
website: www.inserm.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 100˙176˙062 €
 EC max contribution 55˙073˙831 € (55%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2018-Single-Stage-RTD
 Funding Scheme COFUND-EJP
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2023-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) coordinator 12˙066˙181.00
2    ZORGONDERZOEK NEDERLAND ZON NL (DEN HAAG) participant 2˙899˙566.00
3    DEUTSCHES ZENTRUM FUER LUFT - UND RAUMFAHRT EV DE (KOELN) participant 2˙686˙817.00
4    AGENCE NATIONALE DE LA RECHERCHE FR (PARIS) participant 2˙479˙350.00
5    ACADEMISCH ZIEKENHUIS LEIDEN NL (LEIDEN) participant 2˙048˙753.00
6    EUROPEAN MOLECULAR BIOLOGY LABORATORY DE (HEIDELBERG) participant 1˙899˙849.00
7    MINISTERO DELLA SALUTE IT (ROMA) participant 1˙635˙350.00
8    BIOBANKS AND BIOMOLECULAR RESOURCES RESEARCH INFRASTRUCTURE CONSORTIUM (BBMRI-ERIC) AT (GRAZ) participant 1˙620˙071.00
9    ACADEMISCH ZIEKENHUIS GRONINGEN NL (GRONINGEN) participant 1˙372˙748.00
10    UNIVERSITY OF LEICESTER UK (LEICESTER) participant 1˙367˙695.00
11    STICHTING KATHOLIEKE UNIVERSITEIT NL (NIJMEGEN) participant 1˙082˙879.00
12    FUNDACIO CENTRE DE REGULACIO GENOMICA ES (BARCELONA) participant 1˙046˙730.00
13    JOHANN WOLFGANG GOETHE-UNIVERSITATFRANKFURT AM MAIN DE (FRANKFURT AM MAIN) participant 1˙015˙552.00
14    EURORDIS - EUROPEAN ORGANISATION FOR RARE DISEASES ASSOCIATION FR (Paris) participant 930˙665.00
15    FONDAZIONE TELETHON IT (ROMA) participant 929˙539.00
16    FONDATION MALADIES RARES FR (PARIS) participant 908˙920.00
17    AIT AUSTRIAN INSTITUTE OF TECHNOLOGY GMBH AT (WIEN) participant 887˙811.00
18    TURKIYE BILIMSEL VE TEKNOLOJIK ARASTIRMA KURUMU TR (ANKARA) participant 824˙162.00
19    INSTITUTO DE SALUD CARLOS III ES (MADRID) participant 765˙898.00
20    EATRIS ERIC NL (AMSTERDAM) participant 751˙476.00
21    ISTITUTO SUPERIORE DI SANITA IT (ROMA) participant 723˙382.00
22    SCHWEIZERISCHER NATIONALFONDS ZUR FORDERUNG DER WISSENSCHAFTLICHEN FORSCHUNG CH (Bern) participant 714˙035.00
23    ASSISTANCE PUBLIQUE HOPITAUX DE PARIS FR (PARIS) participant 648˙480.00
24    VETENSKAPSRADET - SWEDISH RESEARCH COUNCIL SE (STOCKHOLM) participant 645˙050.00
25    UNIVERSITATSKLINIKUM HEIDELBERG DE (HEIDELBERG) participant 643˙196.00
26    UNIVERSITEIT MAASTRICHT NL (MAASTRICHT) participant 620˙221.00
27    EBERHARD KARLS UNIVERSITAET TUEBINGEN DE (TUEBINGEN) participant 611˙511.00
28    ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM NL (AMSTERDAM) participant 583˙336.00
29    FONDS VOOR WETENSCHAPPELIJK ONDERZOEK-VLAANDEREN BE (BRUSSEL) participant 575˙425.00
30    FONDAZIONE REGIONALE PER LA RICERCA BIOMEDICA IT (MILANO) participant 547˙900.00
31    FONDS ZUR FÖRDERUNG DER WISSENSCHAFTLICHEN FORSCHUNG AT (WIEN) participant 524˙000.00
32    SUOMEN AKATEMIA FI (HELSINKI) participant 512˙750.00
33    NARODOWE CENTRUM BADAN I ROZWOJU PL (WARSZAWA) participant 499˙625.00
34    MINISTRY OF HEALTH IL (JERUSALEM) participant 476˙942.00
35    MINISTRY OF EDUCATION YOUTH AND SPORTS CZ (Prague) participant 470˙400.00
36    UNIVERSITAETSKLINIKUM AACHEN DE (AACHEN) participant 445˙550.00
37    VERKET FOR INNOVATIONSSYSTEM SE (STOCKHOLM) participant 439˙300.00
38    ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK FR (PARIS) participant 418˙573.00
39    CONSORZIO PER VALUTAZIONI BIOLOGICHE E FARMACOLOGICHE IT (BARI) participant 414˙662.00
40    UNIVERSIDAD POLITECNICA DE MADRID ES (MADRID) participant 341˙571.00
41    THE HEALTH RESEARCH BOARD IE (DUBLIN) participant 332˙130.00
42    CHARITE - UNIVERSITAETSMEDIZIN BERLIN DE (BERLIN) participant 319˙056.00
43    INSERM TRANSFERT SA FR (PARIS) participant 315˙000.00
44    FONDS NATIONAL DE LA RECHERCHE LU (ESCH-SUR-ALZETTE) participant 283˙492.00
45    FONDS DE LA RECHERCHE SCIENTIFIQUE- FNRS BE (BRUXELLES) participant 248˙260.00
46    ACIBADEM UNIVERSITESI TR (ISTANBUL) participant 223˙365.00
47    NEMZETI KUTATASI FEJLESZTESI ES INNOVACIOS HIVATAL HU (BUDAPEST) participant 190˙025.00
48    MINISTERO DELL'ISTRUZIONE, DELL'UNIVERSITA' E DELLA RICERCA IT (ROMA) participant 185˙086.00
49    INFRAFRONTIER GMBH DE (NEUHERBERG) participant 182˙756.00
50    FONDAZIONE PER LA RICERCA FARMACOLOGICA GIANNI BENZI ONLUS IT (VALENZANO BARI) participant 178˙255.00
51    TEDDY - EUROPEAN NETWORK OF EXCELLENCE FOR PAEDIATRIC CLINICAL RESEARCH IT (PAVIA) participant 173˙113.00
52    HELIOS DR. HORST SCHMIDT KLINIKEN WIESBADEN GMBH DE (WIESBADEN) participant 167˙107.00
53    REGIONE TOSCANA IT (FIRENZE) participant 152˙400.00
54    LUDWIG BOLTZMANN GESELLSCHAFT GMBH AT (WIEN) participant 144˙410.00
55    FUNDACAO PARA A CIENCIA E A TECNOLOGIA PT (LISBOA) participant 143˙325.00
56    BLACKSWAN FOUNDATION CH (VUARRENS) participant 136˙412.00
57    VIESOJI ISTAIGA VILNIAUS UNIVERSITETO LIGONINE SANTAROS KLINIKOS LT (VILNIUS) participant 133˙364.00
58    SLOVENSKA AKADEMIA VIED SK (BRATISLAVA) participant 127˙005.00
59    UNIVERSITAETSKLINIKUM FREIBURG DE (FREIBURG) participant 126˙584.00
60    ST. ANNA KINDERKREBSFORSCHUNG AT (WIEN) participant 113˙610.00
61    Lietuvos mokslo taryba LT (Vilnius) participant 99˙388.00
62    INSTYTUT POMNIK CENTRUM ZDROWIA DZIECKA PL (WARSZAWA) participant 87˙155.00
63    KATHOLIEKE UNIVERSITEIT LEUVEN BE (LEUVEN) participant 85˙037.00
64    WARSZAWSKI UNIWERSYTET MEDYCZNY PL (WARSZAWA) participant 81˙255.00
65    ISTITUTO ORTOPEDICO RIZZOLI IT (BOLOGNA) participant 77˙661.00
66    GREAT ORMOND STREET HOSPITAL FOR CHILDREN NHS FOUNDATION TRUST UK (LONDON) participant 76˙728.00
67    THE UNIVERSITY OF LIVERPOOL UK (LIVERPOOL) participant 69˙711.00
68    UNIVERSITY OF NEWCASTLE UPON TYNE UK (NEWCASTLE UPON TYNE) participant 66˙412.00
69    CONSORCIO CENTRO DE INVESTIGACION BIOMEDICA EN RED M.P. ES (MADRID) participant 61˙853.00
70    SOTSIAALMINISTEERIUM EE (TALLINN) participant 55˙575.00
71    HACETTEPE UNIVERSITESI TR (CANKAYA ANKARA) participant 51˙271.00
72    SERVICIO MADRILENO DE SALUD ES (MADRID) participant 48˙405.00
73    GDANSKI UNIWERSYTET MEDYCZNY PL (GDANSK) participant 43˙840.00
74    THE NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST UK (NEWCASTLE-UPON-TYNE) participant 42˙011.00
75    CENTRE DE LUTTE CONTRE LE CANCER LEON BERARD FR (LYON) participant 28˙061.00
76    ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM NL (ROTTERDAM) participant 24˙622.00
77    IMAGINE INSTITUT DES MALADIES GENETIQUES NECKER ENFANTS MALADES FONDATION FR (PARIS 15) participant 23˙537.00
78    AZIENDA OSPEDALIERA UNIVERSITARIA SENESE IT (SIENA) participant 21˙223.00
79    GENIKI GRAMMATIA EREVNAS KAI TECHNOLOGIAS EL (ATHENS) participant 20˙658.00
80    INSTITUTO NACIONAL DE SAUDE DR. RICARDO JORGE PT (LISBOA) participant 14˙026.00
81    AZIENDA OSPEDALIERO UNIVERSITARIA PISANA IT (PISA) participant 12˙311.00
82    HOPITAUX UNIVERSITAIRES DE STRASBOURG FR (STRASBOURG CEDEX) participant 11˙900.00
83    VALSTS IZGLITIBAS ATTISTIBAS AGENTURA LV (RIGA) participant 10˙185.00
84    ASS FRANCAISE CONTRE LES MYOPATHIES FR (PARIS) participant 5˙162.00
85    EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL BE (Brussels) participant 5˙162.00
86    CANADIAN INSTITUTES OF HEALTH RESEARCH CA (OTTAWA ONTARIO) participant 0.00
87    DEUTSCHE FORSCHUNGSGEMEINSCHAFT DE (BONN) participant 0.00
88    FONDS DE RECHERCHE DU QUEBEC - SANTE CA (MONTREAL QUEBEC) participant 0.00

Map

 Project objective

As recognized by the Council Recommendation 2009/C 151/02, rare diseases (RD) are a prime example of a research area that can strongly profit from coordination on a European and international scale. RD research should be improved to overcome fragmentation, leading to efficacious use of data and resources, faster scientific progress and competitiveness, and most importantly to decrease unnecessary hardship and prolonged suffering of RD patients. In the specific context of the massive generation, need for reuse and efficient interpretation of data, introduction of omics into care practice and the structuration of RD care centers in European Reference Networks, it appears crucial and timely to maximize the potential of already funded tools and programmes by supporting them further, scaling up, linking, and most importantly, adapting them to the needs of end-users through implementation tests in real settings. Such a concerted effort is necessary to develop a sustainable ecosystem allowing a virtuous circle between RD care, research and medical innovation. To achieve this goal, the European Joint Programme on RD (EJP RD) has two major objectives: (i) To improve the integration, the efficacy, the production and the social impact of research on RD through the development, demonstration and promotion of Europe/world-wide sharing of research and clinical data, materials, processes, knowledge and know-how; (ii) To implement and further develop an efficient model of financial support for all types of research on RD (fundamental, clinical, epidemiological, social, economic, health service) coupled with accelerated exploitation of research results for benefit of patients. To this end, the EJP RD actions will be organized within four major Pillars assisted by the central coordination: (P1): Funding of research; (P2): Coordinated access to data and services; (P3) Capacity building; (P4): Accelerated translation of research projects and improvement outcomes of clinical studies.

 Publications

year authors and title journal last update
List of publications.
2020 Annika Jacobsen, Rajaram Kaliyaperumal, Luiz Olavo Bonino da Silva Santos, Barend Mons, Erik Schultes, Marco Roos, Mark Thompson
A Generic Workflow for the Data FAIRification Process
published pages: 56-65, ISSN: 2641-435X, DOI: 10.1162/dint_a_00028
Data Intelligence 2/1-2 2020-04-25
2020 Annalisa Landi, Mark Thompson, Viviana Giannuzzi, Fedele Bonifazi, Ignasi Labastida, Luiz Olavo Bonino da Silva Santos, Marco Roos
The “A” of FAIR – As Open as Possible, as Closed as Necessary
published pages: 47-55, ISSN: 2641-435X, DOI: 10.1162/dint_a_00027
Data Intelligence 2/1-2 2020-04-25
2020 Annika Jacobsen, Ricardo de Miranda Azevedo, Nick Juty, Dominique Batista, Simon Coles, Ronald Cornet, Mélanie Courtot, Mercè Crosas, Michel Dumontier, Chris T. Evelo, Carole Goble, Giancarlo Guizzardi, Karsten Kryger Hansen, Ali Hasnain, Kristina Hettne, Jaap Heringa, Rob W.W. Hooft, Melanie Imming, Keith G. Jeffery, Rajaram Kaliyaperumal, Martijn G. Kersloot, Christine R. Kirkpatrick, Tobias K
FAIR Principles: Interpretations and Implementation Considerations
published pages: 10-29, ISSN: 2641-435X, DOI: 10.1162/dint_r_00024
Data Intelligence 2/1-2 2020-04-25

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EJP RD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EJP RD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

RESHAPE (2019)

Reshaping undesired Inflammation in challenged Tissue Homeostasis by Next-Generation regulatory T cell (Treg) Approaches – from Advanced Technology Developments to First-in-Human Trials

Read More  

ESCALON (2019)

European-Latin American network for the assessment of biomarkers to predict and diagnose hepatobiliary malignancies and characterization of risk factors for cancer development

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More